Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 [lenalidomide] Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010.
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 29 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Sep 2012 Planned End Date changed from 1 Dec 2010 to 1 Dec 2014, according to Clinicaltrials.gov record (NCT00622336).
- 20 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.